Search

Your search keyword '"Wen, Patrick Y"' showing total 113 results

Search Constraints

Start Over You searched for: Author "Wen, Patrick Y" Remove constraint Author: "Wen, Patrick Y" Publisher springer science and business media llc Remove constraint Publisher: springer science and business media llc
113 results on '"Wen, Patrick Y"'

Search Results

1. Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

3. Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping

4. Liquid biopsy epigenomic profiling for cancer subtyping

5. Clinical trial links oncolytic immunoactivation to survival in glioblastoma

6. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

8. Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival

9. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling

10. Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

11. Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

12. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

13. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

15. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

16. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma

19. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis

22. Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET

27. Mechanisms and therapeutic implications of hypermutation in gliomas

29. A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

31. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors

32. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

33. Local control after brain-directed radiation in patients with cystic versus solid brain metastases

34. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium

35. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

36. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide

38. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

39. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone

40. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival

42. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas

45. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma

46. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate

Catalog

Books, media, physical & digital resources